Get the Stockscreener App
29.55
11.43%
3.03
Pre-market:
29.73
0.18
+0.61%
Viking Therapeutics Inc stock is traded at $29.55, with a volume of 7.48M.
It is up +11.43% in the last 24 hours and up +0.78% over the past month.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$26.52
Open:
$27.69
24h Volume:
7.48M
Relative Volume:
1.78
Market Cap:
$3.32B
Revenue:
-
Net Income/Loss:
$-99.15M
P/E Ratio:
-31.77
EPS:
-0.93
Net Cash Flow:
$-74.25M
1W Performance:
+5.76%
1M Performance:
+0.78%
6M Performance:
-52.95%
1Y Performance:
-55.96%
1-Day Range:
$27.59
$30.14
1-Week Range:
$24.44
$30.55
52-Week Range:
$24.44
$89.10
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
29.55 | 3.32B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-07-25 | Initiated | Citigroup | Neutral |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Nov-22-24 | Initiated | B. Riley Securities | Buy |
| Nov-04-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-24 | Initiated | JP Morgan | Overweight |
| Jun-27-24 | Initiated | Morgan Stanley | Overweight |
| May-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-26-24 | Reiterated | Oppenheimer | Outperform |
| Mar-07-24 | Initiated | Jefferies | Buy |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| May-31-23 | Resumed | ROTH MKM | Buy |
| Mar-28-23 | Reiterated | Maxim Group | Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| May-01-20 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-25-19 | Initiated | Stifel | Buy |
| Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-14-19 | Reiterated | Maxim Group | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-18-18 | Reiterated | Maxim Group | Buy |
| Sep-18-18 | Reiterated | Raymond James | Outperform |
| Jul-20-18 | Initiated | SunTrust | Buy |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-01-18 | Reiterated | Laidlaw | Buy |
| May-31-18 | Reiterated | Maxim Group | Buy |
| Mar-26-18 | Resumed | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | Maxim Group | Buy |
| Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
Viking Therapeutics (NASDAQ:VKTX) Earns “Buy” Rating from HC Wainwright - Defense World
Why Viking Therapeutics Inc. (VKTX) Is Skyrocketing Today? - Insider Monkey
Why VKTX Stock is Moving Today - GuruFocus.com
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped - Yahoo
Viking Therapeutics’ new contract is a game changer. Here’s how much it money it could mean. - MarketWatch
Behind the Scenes of Viking Therapeutics's Latest Options Trends - Benzinga
B. Riley sees two key positives in Viking manufacturing agreement - Yahoo Finance
Viking Therapeutics call volume above normal and directionally bullish - TipRanks
Viking shares slip after manufacturing deal announced - The Pharma Letter
VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug Supply - Yahoo Finance
Viking Therapeutics Is Ready For A Standalone Future (NASDAQ:VKTX) - Seeking Alpha
Viking Therapeutics Secures Strategic Manufacturing Agreement with CordenPharma, Boosting Growth Potential and Earning Buy Rating - TipRanks
Viking Therapeutics Secures Strategic Manufacturing Agreement, Boosting Investor Confidence and Phase 3 Trial Prospects - TipRanks
Bank of New York Mellon Corp Grows Position in Viking Therapeutics, Inc. (NASDAQ:VKTX) - Defense World
Health Care Down on Flight From Biotech, Obesity Drug Makers -- Health Care Roundup - Marketscreener.com
Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735 - The Malaysian Reserve
CordenPharma and Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables and Oral Formulations - BioSpace
Viking Therapeutics: Finally, Here Comes The Buying Opportunity (Upgrade) - Seeking Alpha
Stellantis, Tesla, Viking Therapeutics: Market Minute - Yahoo Finance
Viking Therapeutics closer to bringing its Ozempic competitor to market - Yahoo Finance
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy? - MSN
Viking Therapeutics Signs Broad Manufacturing Agreement with CordenPharma - Contract Pharma
Cordenpharma, Viking Therapeutics form long-term partnership to provide key materials to make injectable and oral medications - Marketscreener.com
Viking Therapeutics stock in focus after CDMO deal (VKTX) - Seeking Alpha
H.C. Wainwright maintains Buy on Viking Therapeutics stock By Investing.com - Investing.com UK
Viking Therapeutics Signs Manufacturing Deal With CordenPharma for Obesity Program - Marketscreener.com
Viking Therapeutics inks production deal for obesity drug - MSN
CordenPharma and Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables and Oral Formulations – Company AnnouncementFT.com - Financial Times
Viking Therapeutics secures supply for obesity drug - Investing.com India
Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735 – Company AnnouncementFT.com - Financial Times
Is Eli Lilly Stock a Buy? - The Motley Fool
Viking Therapeutics: Signs Of Insufficient Differentiation In Obesity Treatment (Rating Downgrade) - Seeking Alpha
H.C. Wainwright says Novo results support Viking obesity potential - TipRanks
Promising Potential of Viking Therapeutics’ VK2735 in Obesity and Diabetes Treatment Drives Buy Rating - TipRanks
This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street - sharewise
Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs - AOL
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know - MSN
7 Best Weight Loss Drug Stocks to Buy in 2025 | Investing | U.S. News - U.S News & World Report Money
Viking Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
BJ's Wholesale Club Posts Better-Than-Expected Earnings, Joins Burlington Stores, Veeva Systems And Other Big Stocks Moving Higher On Thursday - Benzinga
Why Viking Therapeutics Shares Are Climbing Higher - TipRanks
Why Viking Therapeutics, Inc. (VKTX) Soared on Tuesday - MSN
Viking Therapeutics to Participate at Upcoming Investor Conferen - GuruFocus.com
Can Viking Therapeutics' March Conference Appearances Signal New Development Updates? - StockTitan
Viking Therapeutics Unusual Options Activity - Benzinga
(VKTX) Investment Report - Stock Traders Daily
Viking Therapeutics, Inc. (VKTX) Ascends But Remains Behind Market: Some Facts to Note - MSN
Viking Therapeutics Defies Financial Storms: The VK2735 Weight Loss Revolution - Jomfruland.net
Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval? - MSN
How Viking Therapeutics is Revolutionizing Health with Breakthrough Biotech Solutions - Jomfruland.net
Is Viking Therapeutics, Inc. (VKTX) the Worst Performing Mid Cap Stock to Buy According to Analysts? - Insider Monkey
Viking Therapeutics Inc Stock (VKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):